A MEDLINE search of the English-language literature (1990–August 2001) was performed using the key terms orlistat, obesity, glucose, and diabetes.
DATA EXTRACTION:
All articles pertaining to orlistat were considered for inclusion, with emphasis placed on randomized, placebo-controlled, double-blind clinical trials.
DATA SYNTHESIS:
In April 1999, orlistat was approved by the Food and Drug Administration for the treatment of obesity. Of 13 randomized, placebo-controlled studies, only 2 reported specific data in individuals with type 2 diabetes. Both reported significant weight reduction and improved glycemic control over placebo.
CONCLUSIONS:
Since weight loss is a difficult goal to achieve in patients with type 2 diabetes, orlistat can be a safe, effective addition to a multidisciplinary approach.
Early release of selected estimates from the national health interview survey, data from year 2000 and early 2001, obesity. September 20, 2001. National Center for Health Statistics, Centers for Disease Control and Prevention [cited 2001 Sept 22]. Available from: URL: http://www.cdc.gov/nchs/about/major/nhis/earlyrelease2000.htm.
2.
Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med1998;158: 1855–67.
3.
National diabetes fact sheet, prevalence of diabetes. November 1, 1998. National Center for Chronic Disease Prevention and Health Promotion, Diabetes Public Health Resource [cited 2001 Sept 14]. Available from URL: http://www.cdc.gov/diabetes/pubs/facts98.htm#prev.
4.
MaggioCAPi-SunyerFX. The prevention and treatment of obesity. Application to type 2 diabetes. Diabetes Care1997;20: 1744–66.
5.
ManningRMJungRTLeeseGPNewtonRW. The comparison of four weight reduction strategies aimed at overweight diabetic patients. Diabet Med1995;12: 409–15.
6.
PerryIJWannametheeSGWalkerMKThomsonAGWhincupPHShaperAG. Prospective study of risk factors for development of non-insulin—dependent diabetes in middle aged British men. BMJ1995;310: 560–4.
7.
HunterSJGarveyWT. Insulin action and insulin resistance: Diseases involving defects in insulin receptors, signal transduction, and the glucose transport effector system. Am J Med1998;105: 331–45.
8.
SpeechlyDPBuffensteinR. Appetite dysfunction in obese males: Evidence for role of hyperinsulinaemia in passive overconsumption with a high fat diet. Eur J Clin Nutr2000;54: 225–33.
9.
DavisTMMillnsHStrattonIMHolmanRRTurnerRC. Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29. Arch Intern Med1999;159: 1097–103.
10.
DeFronzoRAFerranniniE. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care1991;14: 173–94.
11.
MeigsJBMittlemanMANathanDMToflerGHSingerDEMurphy-SheehyPMHyperinsulinemia, hyperglycemia, and impaired hemostasis: The Framingham Offspring Study. JAMA2000;283: 221–8.
12.
WilsonPWKannelWBSilbershatzHD'AgostinoRB. Clustering of metabolic factors and coronary heart disease. Arch Intern Med1999;159: 1104–9.
13.
American Diabetes Association Clinical Practice Recommendations 2001. Diabetes Care2001;24(suppl 1):S1–133.
14.
WingRREpsteinLHPaternostro-BaylesMKriskaANowalkMPGoodingW. Exercise in a behavioural weight control programme for obese patients with type 2 (non-insulin-dependent) diabetes. Diabetologia1988;31: 902–9.
15.
BouleNGHaddadEKennyGPWellsGASigalRJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: A meta-analysis of controlled clinical trials. JAMA2001;286: 1218–27.
16.
BerkeEMMordenNE. Medical management of obesity. Am Fam Physician2000;62: 419–26.
17.
WingRR. Physical activity in the treatment of the adulthood overweight and obesity: Current evidence and research issues. Med Sci Sports Exerc1999;31:S547–52.
18.
WannametheeSGShaperAGAlbertiKG. Physical activity, metabolic factors, and the incidence of coronary heart disease and type 2 diabetes. Arch Intern Med2000;160: 2108–16.
19.
TorjesenPABirkelandKIAnderssenSAHjermannIHolmeIUrdalP. Lifestyle changes may reverse development of the insulin resistance syndrome. The Oslo Diet and Exercise Study: A randomized trial. Diabetes Care1997;20: 26–31.
20.
ScheenAJ. Treatment of diabetes in patients with severe obesity. Biomed Pharmacother2000;54: 74–9.
21.
BaikIAscherioARimmEBGiovannucciESpiegelmanDStampferMJAdiposity and mortality in men. Am J Epidemiol2000;152: 264–71.
22.
LeanMEPowrieJKAndersonASGarthwaitePH. Obesity, weight loss and prognosis in type 2 diabetes. Diabet Med1990;7: 228–33.
23.
WilliamsonDFThompsonTJThunMFlandersDPamukEByersT. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care2000;23: 1499–504.
24.
TorgersonJSSjostromL. The Swedish Obese Subjects (SOS) study—rationale and results. Int J Obes Relat Metab Disord2001;25(suppl 1):S2–4.
25.
GrayARaikouMMcGuireAFennPStevensRCullCCost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: Economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group. BMJ2000;320: 1373–8.
26.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352: 837–53.
27.
Implications of the United Kingdom Prospective Diabetes Study. American Diabetes Association. Diabetes Care1998;21: 2180–4.
28.
WillmsBRugeD. Comparison of acarbose and metformin in patients with type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: A randomized, placebo-controlled study. Diabet Med1999;16: 755–61.
29.
PasqualiRGambineriABiscottiDVicennatiVGagliardiLColittaDEffect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab2000;85: 2767–74.
30.
LandgrafRFrankMBauerCDiekenML. Prandial glucose regulation with repaglinide: Its clinical and lifestyle impact in a large cohort of patients with type 2 diabetes. Int J Obes Relat Metab Disord2000;24 (suppl 3):S38–44.
31.
MosesRGGomisRFrandsenKBSchliengerJLDedovI. Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naïve type 2 diabetes. Diabetes Care2001;24: 11–5.
32.
WoleverTMChiassonJLJosseRGHuntJAPalmasonCRodgerNWSmall weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes. Int J Obes Relat Metab Disord1997;21: 756–63.
33.
United Kingdom Prospective Diabetes Study 24: A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group. Ann Intern Med1998;128: 165–75.
34.
ScheenAJLefebvrePJ. Troglitazone: Antihyperglycemic activity and potential role in the treatment of type 2 diabetes. Diabetes Care1999;22: 1568–77.
35.
CamachoPPitaleSAbrairaC. Beneficial and detrimental effects of intensive glycaemic control, with emphasis on type 2 diabetes mellitus. Drugs Aging2000;17: 463–76.
36.
BuseJ. Combining insulin and oral agents. Am J Med2000;108(suppl 6a):23S–32S.
37.
ScheenAJ. Clinical efficacy of acarbose in diabetes mellitus: A critical review of controlled trials. Diabetes Metab1998;24: 311–20.
38.
Adverse events and their association with treatment regimens in the Diabetes Control and Complications Trial. Diabetes Care1995;18: 1415–27.
39.
WingRRKleinRMossSE. Weight gain associated with improved glycemic control in population-based sample of subjects with type I diabetes. Diabetes Care1990;13: 1106–9.
40.
DalyPALandsbergL. Hypertension in obesity and NIDDM. Role of insulin and sympathetic nervous system. Diabetes Care1991;14: 240–8.
41.
BogardusCTaskinenMRZawadzkiJLilliojaSMottDHowardBV. Increased resting metabolic rates in obese subjects with non-insulin-dependent diabetes mellitus and the effect of sulfonylurea therapy. Diabetes1986;35: 1–5.
42.
GuareJCWingRRGrantA. Comparison of obese NIDDM and nondiabetic women: Short- and long-term weight loss. Obes Res1995;3: 329–35.
43.
KhanMASt PeterJVBreenGAHartleyGGVesseyJT. Diabetes disease stage predicts weight loss outcomes with long-term appetite suppressants. Obes Res2000;8: 43–8.
44.
PaiseyRBHarveyPRiceSBelkaIBowerLDunnMAn intensive weight loss programme in established type 2 diabetes and controls: Effects on weight and atherosclerosis risk factors at 1 year. Diabet Med1998;15: 73–9.
45.
Endocrinologic and Metabolic Drugs Advisory Committee Meeting Proceedings. Bethesda, MD: Food and Drug Administration, March 13, 1998.
46.
Package insert. Xenical (orlistat). Nutley, NJ: Roche Pharmaceuticals, September 2000.
LucasKHKaplan-MachlisB. Orlistat—a novel weight loss therapy. Ann Pharmacother2001;35: 314–28.
50.
HeckAMYanovskiJACalisKA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy2000;20: 270–9.
51.
GuercioliniR. Mode of action of orlistat. Int J Obes Relat Metab Disord1997;21(suppl 3):S12–23.
52.
ZhiJMeliaATKoss-TwardySGMinBGuercioliniRFreundlichNLThe influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers. J Clin Pharmacol1995;35: 521–5.
53.
ZhiJMeliaATFunkCViger-ChougnetAHopfgartnerGLauseckerBMetabolic profiles of minimally absorbed orlistat in obese/overweight volunteers. J Clin Pharmacol1996;36: 1006–11.
54.
HauptmanJBJeunetFSHartmannD. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18–0647 (tetrahydrolipstatin). Am J Clin Nutr1992;55:309S–13S.
55.
Diet, average daily intakes. 1988–91. National Centers for Health Statistics, Centers for Disease Control and Prevention [cited 2001 Sept 14]. Available from: URL: www.cdc.gov/nchc/fastats/diet.htm.
56.
HollanderPAElbeinSCHirschIBKelleyDMcGillJTaylorTRole of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care1998;21: 1288–94.
57.
LindgardeF. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study. J Intern Med2000;248: 245–54.
58.
RossnerSSjostromLNoackRMeindersAENosedaG. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res2000;8: 49–61.
59.
DavidsonMHHauptmanJDiGirolamoMForeytJPHalstedCHHeberDWeight control and risk factor reduction in obese subjects treated for 2 years with orlistat: A randomized controlled trial. JAMA1999;281: 235–42.
60.
SjostromLRissanenAAndersenTBoldrinMGolayAKoppeschaarHPRandomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet1998;352: 167–72.
61.
WaddenTABerkowitzRIWombleLGSarwerDBArnoldMESteinbergCM. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: A placebo-controlled trial. Obes Res2000;8: 431–7.
62.
HillJOHauptmanJAndersonJWFujiokaKO'NeilPMSmithDKOrlistat, a lipase inhibitor, for weight maintenance after conventional dieting: A 1-year study. Am J Clin Nutr1999;69: 1108–16.
63.
DrentMLPopp-SnijdersCAderHJJansenJBVan der VeenEA. Lipase inhibition and hormonal status, body composition and gastrointestinal processing of a liquid high-fat mixed meal in moderately obese subjects. Obes Res1995;3: 573–81.
64.
JamesWPAvenellABroomJWhiteheadJ. A one-year trial to assess the value of orlistat in the management of obesity. Int J Obes Relat Metab Disord1997;21(suppl 3):S24–30.
65.
ZavoralJH. Treatment with orlistat reduces cardiovascular risk in obese patients. J Hypertens1998;16: 2013–7.
66.
FinerNJamesWPKopelmanPGLeanMEWilliamsG. One-year treatment of obesity: A randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord2000;24: 306–13.
67.
Van GaalLFBroomJIEnziGToplakH. Efficacy and tolerability of orlistat in the treatment of obesity: A 6-month dose-ranging study. Orlistat Dose-Ranging Study Group. Eur J Clin Pharmacol1998;54: 125–32.
68.
HauptmanJLucasCBoldrinMNCollinsHSegalKR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med2000;9: 160–7.
69.
HeymsfieldSBSegalKRHauptmanJLucasCPBoldrinMNRissanenAEffects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med2000;160: 1321–6.
70.
ZhiJMeliaATGuercioliniRKoss-TwardySGPasseSMRakhitAThe effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol1996;36: 659–66.
71.
ZhiJMeliaATKoss-TwardySGAroraSPatelIH. The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers. J Clin Pharmacol1996;36: 152–9.
72.
MeliaATZhiJKoss-TwardySGMinBHSmithBLFreundlichNLThe influence of reduced dietary fat absorption induced by orlistat on the pharmacokinetics of digoxin in healthy volunteers. J Clin Pharmacol1995;35: 840–3.
73.
MeliaATKoss-TwardySGZhiJ. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol1996;36: 647–53.
74.
Le BellerCBezieYChabatteCGuillemainRAmreinCBillaudEM. Coadministration of orlistat and cyclosporine in a heart transplant recipient (letter). Transplantation2000;70: 1541–2.
75.
SchnetzlerBKondo-OstreicherMValaDKhatchatourianGFaiduttiB. Orlistat decreases the plasma level of cyclosporine and may be responsbile for the development of acute rejection episodes (letter). Transplantation2000;70: 1540–1.
76.
NageleHPetersenBBonackerURodigerW. Effect of orlistat on blood cyclosporine concentration in an obese heart transplant patient. Eur J Clin Pharmacol1999;55: 667–9.
77.
ErrastiP. Garcia I, Lavilla J, Ballester B, Manrique J, Purroy A. Reduction in blood cyclosporine concentration by Orlistat in two renal transplant patients. Transplant Proc2002;34: 137–9.
78.
ValseciaME MLFariasEFFiguerasA. Interaction between orlistat and antihypertensive drugs. Ann Pharmacother2001;35: 1493–4.
79.
PerssonMVitolsSYueQY. Orlistat associated with hypertension. BMJ2000;321:87.
80.
WolfAMColditzGA. Current estimates of the economic cost of obesity in the United States. Obes Res1998;6: 97–106.
81.
CollinsRWAndersonJW. Medication cost savings associated with weight loss for obese non-insulin-dependent diabetic men and women. Prev Med1995;24: 369–74.
82.
GreenwayFLRyanDHBrayGARoodJCTuckerEWSmithSR. Pharmaceutical cost savings of treating obesity with weight loss medications. Obes Res1999;7: 523–31.
83.
Drug topics red book. vol. 2001. Montvale, NJ: Medical Economics, 2001.
84.
Yki-JarvinenHRyysyLNikkilaKTulokasTVanamoRHeikkilaM. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med1999;130: 389–96.
85.
WingRRKoeskeREpsteinLHNowalkMPGoodingWBeckerD. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med1987;147: 1749–53.
86.
HoffmannJSpenglerM. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study. Diabetes Care1994;17: 561–6.
87.
JohnstonPSLebovitzHEConiffRFSimonsonDCRaskinPMuneraCL. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab1998;83: 1515–22.
88.
JohansenK. Efficacy of metformin in the treatment of NIDDM. Meta-analysis. Diabetes Care1999;22: 33–7.
89.
JohnstonPSConiffRFHoogwerfBJSantiagoJVPi-SunyerFXKrolA. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients. Diabetes Care1994;17: 20–9.
90.
FuchtenbuschMStandlESchatzH. Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes2000;108: 151–63.
91.
FujiokaKSeatonTBRoweEJelinekCARaskinPLebovitzHEWeight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab2000;2: 175–87.
92.
FinerNBloomSRFrostGSBanksLMGriffithsJ. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: A randomised, double-blind, placebo-controlled study. Diabetes Obes Metab2000;2: 105–12.
93.
GokcelAKarakoseHErtorerEMTanaciNTutuncuNBGuvenerN. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care2001;24: 1957–60.
94.
DujovneCAZavoralJHRoweEMendelCM. Effects of sibutramine on body weight and serum lipids: A double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. Am Heart J2001;142: 489–97.
95.
Berube-ParentSPrud'hommeDSt-PierreSDoucetETremblayA. Obesity treatment with a progressive clinical tri-therapy combining sibutramine and a supervised diet-exercise intervention. Int J Obes Relat Metab Disord2001;25: 1144–53.
